thebench.bio

Funding Daily Summary

Funding Daily Summary: What Happened on October 6, 2026

RougeTx launches with $58 million to advance rare-disease drug

Sensible Biotechnologies and WhiteLab Genomics also raised funding for mRNA manufacturing and gene-delivery technologies.

  • Updated
  • Read from 3 articles, 2 publications

Today in brief

RougeTx launched with a $58 million Series A to move its hereditary hemorrhagic telangiectasia candidate RTX-001 toward its first human trial.1 Sensible Biotechnologies raised $47 million, including potential government and European Union support, while WhiteLab Genomics raised $26 million for its gene-delivery platform.23

Also worth knowing

  • Sensible plans to expand VECTOR, its mRNA design and screening platform, and build capacity to make clinical-grade material. Up to $20 million of the financing is potential non-dilutive support from Slovakia and the European Union.2

  • WhiteLab will use its $26 million Series B to test AI-designed gene-delivery components and develop assets it can own and license, including adeno-associated viruses and nonviral methods such as lipid nanoparticles.3

Also published